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http://dx.doi.org/10.1016/j.jadohealth.2016.03.040Neisseria meningitidis, an exclusively human pathogen, is a
major cause of invasive meningococcal disease (IMD), most often
manifesting as septicemia with or without meningitis that can
lead to death within 24e48 hours of symptom onset [1]. IMD
incidence is highest in infants and children (<5 years old), ado-
lescents and young adults (16e21 years old), and the elderly
(65 years old) [2]. The case:fatality ratio of IMD generally
ranges from approximately 10%e20% [1e6]. Moreover, nearly20% of survivors experience signiﬁcant sequelae including limb
loss, hearing loss, chronic pain, skin scarring, and neurologic
deﬁcits [7].
Most cases of IMD are sporadic, but they can be associated
with outbreaks, making them highly unpredictable [8,9]. The
volatile nature of disease is emphasized by the four meningo-
coccal serogroup B (MnB) outbreaks occurring at universities in
the United States since 2013. The sometimes poor prognosis of
infected patients, coupled with the unpredictability of disease
onset and progression, suggests an urgent need for implement-
ing effective prevention.
Person-to-person transmission can be interrupted by either
chemoprophylaxis (i.e., antibiotic administration) or immuno-
prophylaxis (i.e., immunization). Prophylaxis with antibiotics,
such as rifampin, quinolones, or ceftriaxone, are used to prevent
Table 1
U.S. licensed meningococcal vaccines and current ACIP recommendations
Vaccine Licensure (age; year) ACIP recommendation, dose:population
General population High-risk groupsa
Category Primary Booster
MenACWY vaccines
MenACWY-D (Menactra; Sanoﬁ Pasteur) 2e55 years; 2005
9e23 months; 2011
A One dose [2]: age 11e12 years
or 13e18 years if not
previously immunized
Catch-up: age 19e21 years for
those who have not
received a dose after age
16 years.
One dose:
if ﬁrst dose
before age
16 years
Two doses, 12 weeks apart:
age 9e23 months
(Menactra).b,c,d
Four doses at 2, 4, 6, and
12 months: age 2
e23 months (Menveo
[26]).b,c,d,e
Two doses, 8e12 weeks
apart: age 2e55 years,
not immunized
previously.d,e
One dose: age 2e55 years,
not immunized
previously [26].b,c,f,g
MenACWY-CRM (Menveo; GlaxoSmithKline) 2e55 years; 2010
2 months; 2013
A
MenCY vaccines
Hib-MenCY-TT (MenHibrix; GlaxoSmithKline) 6 weekse18 months;
2012
A N/A N/A Four doses at 2, 4, 6, and 12
e15 mo: age 2e18 mo
[2].c,d,e
MenB vaccines
Bivalent rLP2086 (Trumenba; Pﬁzer Inc) 10e25 years; 2014 B Twoethree doses: age 16e23
years, in consultation with
health care provider [27].h
N/A Twoethree doses: age
10 years [28].c,d,e,g4CMenB (Bexsero; GlaxoSmithKline) 10e25 years; 2015 B
ACIP ¼ Advisory Committee on Immunization Practices; N/A ¼ not applicable.
a Individuals remaining at increased risk of meningococcal disease should receive an MenACWY booster 3 or 5 years after completing the primary immunization at
age 2 monthse6 years or 7 years, respectively. Boosters should be repeated every 5 years thereafter.
b Individuals traveling to locations or who are residents of countries where meningitis is hyperendemic or epidemic.
c Community outbreaks caused by a vaccine serogroup.
d Individuals with persistent complement deﬁciencies, including those being treated with eculizumab (Solaris).
e Individuals with functional or anatomic asplenia (including sickle cell disease).
f Individuals who are ﬁrst-year college students aged 21 years living in residential housing.
g Microbiologists who routinely work with Neisseria meningitidis isolates.
h 4CMenB is licensed as a two-dose series, with doses administered 1 month apart; Bivalent rLP2086 is licensed as a three-dose series, with the second and third
doses administered 1-2 and 6 months after the ﬁrst dose. In addition to the three-dose schedule for bivalent rLP2086, recently the Food and Drug Administration has
approved a two-dose series (0 and 6 months); the choice of schedule depends on the risk of exposure and the patient’s susceptibility to disease.
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patient [10,11]; detailed guidelines for their use already are
described [12]. This review will focus on immunization as a
preventive strategy, with an in-depth discussion of the available
meningococcal vaccines in the United States, current recom-
mendations for their use, lessons learned from previous experi-
ences, and future considerations.
Assessment of Meningococcal Vaccine Effectiveness
Because of the low incidence of IMD in the United States,
generally <1 per 100,000 persons [13], large-scale Phase 3 vac-
cine efﬁcacy studies are not feasible because of ﬁnancial and lo-
gistic difﬁculties. Therefore, alternative in vitro functional assays
that mimic the main mechanism of protection observed in vivo
were developed to assess the potential efﬁcacy of a meningo-
coccal vaccine in a population. Speciﬁcally, complement-
dependent bactericidal activity of antibodies derived from the
serum of individuals after immunization with meningococcal
antigens is used as a surrogate (or correlate) of protection [14].
This correlate is measured with an assay referred to as a serum
bactericidal antibody assay and is performed using human com-
plement (hSBA) [2]. hSBA assays are the U.S. Food and Drug
Administration’s (FDA’s) accepted standard for estimating efﬁcacy
of a meningococcal vaccine; an hSBA titer of 1:4 is consideredprotective [14e17]. This threshold has been shown to correlate
with effectiveness in postlicensure studies [18], and hSBA titers
are used to demonstrate protection across meningococcal
serogroups [14,19,20].
Vaccines Available for the Prevention of Invasive
Meningococcal Disease
Serogroup A, C, W, and Y vaccines
Neisseria meningitidis is classiﬁed into serogroups based on
the composition of their capsular polysaccharides (CPSs) [6,21],
with serogroups designated as A, B, C, W, X, and Y attributed to
almost all cases of life-threatening, sporadic, and endemic dis-
ease globally [21e25]. Until recently, meningococcal vaccines
approved in the United States only protected against IMD caused
by four of the six disease-causing serogroups of N meningitides:
A, C, W, and Y.
Four different meningococcal vaccines containing puriﬁed
CPSs alone or CPSs conjugated to a carrier protein are licensed in
the United States for the prevention of IMD caused by serogroups
A, C, W, and Y (Table 1). The quadrivalent CPS vaccine MPSV4
(Menomune [Meningococcal Polysaccharide Vaccine, Groups A,
C, W, and Y combined]; Sanoﬁ Pasteur Inc., Swiftwater, Penn-
sylvania) has been available since the 1970s for use in individuals
Figure 1. Development of serogroup MenACWY polysaccharide conjugate vaccines.
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nization programs in response to outbreaks among international
travelers and in closed populations of adults at high risk for
disease [6,13,29].
MPSV4 has been replaced by the quadrivalent CPS-protein
conjugate vaccines MenACWY-D (Menactra; Sanoﬁ Pasteur Inc.,
licensed 2005) and MenACWY-CRM (Menveo;GlaxoSmithKline
Biologicals, Rixensart, Belgium; licensed 2010), collectively
referred to here as MenACWY for use in individuals nine months
through 55 years of age and individuals 2 months through
55 years of age, respectively [30,31] (Figure 1). A bivalent CPS-
protein conjugate vaccine, Haemophilus inﬂuenzae b-Neisseria
meningitidis serogroups C and Y (Hib-MenCY-TT; MenHibrix;
GlaxoSmithKline Biologicals), was approved in 2012 for use in
individuals six weeks through 18 months of age [32]. These
vaccines differ from MPSV4 vaccine in that their CPSs are con-
jugated to a protein carrier; this carrier protein presents the CPS
to the immune system, resulting in a T-cell response and the
likely added beneﬁts of immunologic memory at re-exposure,
nasopharyngeal carriage reduction, and herd immunity [13,29].
Serogroup B vaccines
There is a need for a broadly protectiveMnB vaccine for use in
the United States, as MnB is responsible for approximately 30%e
40% of all IMD cases in this country [33,34]. Moreover, serogroupB caused the recent outbreaks observed at several university
campuses [28], further emphasizing the need for an effective
MnB vaccine as a preventive measure in this circumstance. Un-
fortunately, the CPS of MnB does not an elicit immune response
owing to its similarity to peptides on human neural tissue [35].
To develop a broadly protective MnB vaccine, identiﬁcation of
surface proteins that elicit a sufﬁcient immune response, that are
present in a majority of disease strains, and that have limited
immunologic variability across diverse serogroup B isolates was
necessary. A conserved surface-exposed bacterial lipoprotein and
hSBA factor H binding protein (fHBP; also known as LP2086)
were identiﬁed as a promising vaccine target [36,37]. Two
protein-based serogroup B vaccines that contain fHBP have been
developed: bivalent rLP2086 (Trumenba [MenB-FHbp]; Pﬁzer
Inc, Philadelphia, Pennsylvania) and 4CMenB (Bexsero [MenB-
4C]; GlaxoSmithKline, Brentford, Middlesex, United Kingdom;
Table 1).
These vaccines employ two different strategies to address
broad coverage across diverse MnB strains. Speciﬁcally, 4CMenB
includes four unrelated meningococcal protein components:
subfamily B fHBP, neisserial adhesin A, neisserial heparin-
binding antigen, and a porin A (PorA) outer membrane vesicle
(Figure 2A). Although none of these proteins address the full
antigenic diversity across all MnB strains, 4CMenB aims to pro-
vide breadth of serogroup B strain coverage by including multi-
ple antigens with the expectation that at least one of the antigens
Figure 2. Development of serogroup B recombinant protein vaccines (A), 4CMenB (B). E.coli ¼ Escherichia coli; NadA¼ neisserial adhesin A; NHBA ¼ neisserial heparin-
binding antigen.
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rLP2086 has only one protein (fHBP) but includes both of its
antigenic variants: fHBP subfamily A and fHBP subfamily B
(Figure 2B). Breadth of strain coverage is accomplished by the
ability of these two proteins to cover the antigenic variability of
fHBP found in all serogroup B strains. Unlike the fHBP subfamily
B variant found in 4CMenB, both of the fHBP variants in bivalent
rLP2086 are modiﬁed by addition of a lipid group, similar to the
naturally occurring protein [36].
Bivalent rLP2086 was licensed in the United States in October
2014 through an accelerated FDA process for use in people aged
10 through 25 years [38]. This was subsequently followed by
accelerated FDA approval of 4CMenB in January 2015 in the same
age group [39]. Not only do these two vaccines differ in antigen
composition, but also they differ in methods used to estimate
breadth of coverage across MnB strain diversity. Although sur-
rogate methods may help predict the potential coverage of the
two vaccines, true effectiveness cannot be determined until there
is enough vaccine uptake to collect large-scale surveillance data.
Recommendations for meningococcal immunization
The Advisory Committee on Immunization Practices (ACIP)
recommends immunization with MenACWY for everyone ages
11 through 18 years (Table 1). The ﬁrst dose ideally should be
given at 11e12 years of age, followed by a booster at age 16 years.
A single dose may be given up until 21 years of age as a catch-up
vaccination if a ﬁrst dose has not been administered before the
age of 16 [2]. MenACWY also is recommended routinely for all
individuals age nine months through 55 years who are
considered to be at high risk for IMD (Table 1) [2]. High-risk in-
dividuals should receive MenACWY in a one- or two-dose series,
depending on the vaccine indication and age of the individual.
Recommendations of the ACIP were recently updated to
include MenACWY for high-risk infants two through 23 months
of age. Immunization should be administered in a four-dose se-
ries, with the ﬁrst booster three years after the primary series, if
necessary [26]. Hib-MenCY-TT also is recommended for high-risk
infants twoe18 months of age, with the ﬁrst dose administered
as early as age six weeks and the fourth dose given as late as age
18 months [2]. This vaccine can be co-administered with other
routine infant vaccines. A booster dose of MenACWY, if needed, is
recommended three years after the last dose of Hib-MenCY-TT.
Recently, the ACIP published vaccination recommendations
for MnB using either 4CMenB or bivalent rLP2086 [27,28]. A
vaccination series also may be used in individuals 16 through
23 years of age, preferably between the ages of 16e18 years, after
consultation with a health care provider to provide short-term
protection against most strains of MnB (category B recommen-
dation) [27]. Vaccination is recommended for individuals aged
10 years who are at high risk for MnB disease [28]. The impli-
cations of these recommendations are discussed inmore detail in
the following section.
Lessons Learned From Past Experiences
Successful implementation of ACWY vaccines
The overall success of a vaccine depends on coverage of the
at-risk population, safety and effectiveness of the vaccine at
preventing disease, and ideally, reduction in carriage acquisition
so that indirect (herd) effects are achieved. Since its introduction,coverage for MenACWY vaccines in adolescents age 13 through
17 years has been steadily increasing, with rates starting at 11.7%
in 2006 [40] and increasing to 79.3% in 2014 [41]. Coverage by
state in 2014 ranged from 46.0% (Mississippi) to 95.2% (Penn-
sylvania) [41]. As vaccine coverage in this age group increased,
IMD incidence for the vaccine serogroups simultaneously
decreased, with rates (95% conﬁdence interval [CI]) per 100,000
people of .27 (.17e.39) from 2004 to 2005 and .05 (.02e.12) from
2010 to 2011 [2].
Although direct effects of the immunized population were
evident, incidence did not decrease in other age groups,
suggesting no evidence of protection in the unimmunized pop-
ulation (i.e., herd effects); however, herd effects from meningo-
coccal vaccines have been demonstrated in other countries when
coverage approaches 90% [42]. A case-control study evaluating
vaccine effectiveness began in January 2006 [43]. As of May 2012,
a total of 151 case patients and 200 controls were enrolled. The
overall estimate of vaccine effectiveness in adolescents was 66%
(95% CI, 24%e84%) in those vaccinated 0e6 years earlier. Vaccine
effectiveness also decreased over time, however; the overlapping
CIs observed must be taken into account when interpreting this
decrease. Speciﬁcally, vaccine effectiveness was estimated at 79%
(95% CI, 47%e92%) for adolescents immunized <1 year earlier,
73% (95% CI, 34%e89%) for adolescents immunized one to
<2 years earlier, 44% (95% CI, 17%e74%) for adolescents immu-
nized 2 to <3 years earlier, and 41% (95% CI, 19%e71%) for ado-
lescents immunized 3 to <6 years earlier.
Important lessons can be garnered from our experiences with
MenACWY vaccines in the United States. Speciﬁcally, vaccine
effectiveness is high in the ﬁrst or second year after primary
immunization; it is likely that herd effects will not be seen until
ﬁrst dose coverage approaches 90%. However, long-term effec-
tiveness after the primary dose is disappointingly short-lived;
this waning effectiveness led to a policy change in adolescents
from a single primary dose to a single primary dose plus a
booster dose [44]. The decision to include a booster dose also
took into consideration other factors such as health care provider
access to adolescents, changing disease epidemiology, and cost-
effectiveness. For herd effects to extend through all of adoles-
cence, second dose coverage, which is currently approximately
30% [45], must increase substantially.
Although these results are encouraging, it should be noted
that the number of cases of IMD caused by all serogroups
diminished signiﬁcantly even before the ﬁrst A,C,W,Y conjugate
vaccine was recommended for adolescents in 2005 [34]. Reasons
for this decrease are not completely understood but may be
attributed to the cyclical nature of disease [13,34]. The demon-
strated effectiveness in adolescents also provides an encouraging
example that strongly supports the continued use of immuni-
zation to reduce disease burden of serogroups A, C, W, and Y.
Whether similar results will be observed after serogroup B vac-
cine implementation remains to be determined.
Use of serogroup B vaccine on college campuses in the United
States
MnB has been responsible for several outbreaks on U.S. col-
lege campuses since 2013 (Table 2). Given the unpredictability of
meningococcal outbreaks, immunization is a strategy for
reducing meningococcal disease incidence and, in combination
with chemoprophylaxis, controlling outbreaks. The lack of an
FDA-licensed serogroup B vaccine presented signiﬁcant
Table 2
Recent MnB outbreaks on college campuses in the United States
University/college Date of outbreak Conﬁrmed
cases, n
Deaths/
amputations, n
Vaccine used Comments
Princeton University [46e48] March 2013eMarch 2014 9 1/0 4CMenB  Lengthy outbreak with uncharacteristically long
gaps between cases
 Several cases occurred off campus
 Lack of licensed MnB vaccine at time of outbreak
presented signiﬁcant challenges
 FDA approved the use of 4CMenB as an investi-
gational new drug; two-dose series
recommended for >5000 students; uptake was
high
University of California,
Santa Barbara [47,48]
November 2013 4 0/1 4CMenB  Lack of licensed MnB vaccine at time of outbreak
presented signiﬁcant challenges
 FDA approved the use of 4CMenB as an investi-
gational new drug; two-dose series
recommended for 20,000 students; uptake was
low
Providence College [45,48] January 2015 2 0/0 Bivalent rLP2086  University moved rapidly to implement a
mandatory campus-based mass immunization
campaign; uptake of Dose 1 was high
University of Oregon [49,50] January 2015epresent 7 1/0 Bivalent rLP2086  Cases being actively managed
 A high percentage of students received Dose 1;
uptake of Dose 2 was much lower
FDA ¼ U.S. Food and Drug Administration; MnB ¼ meningococcal serogroup B.
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Princeton University and the University of California, Santa Bar-
bara [51]. The outbreak at Princeton University lasted a full year
(March 2013eMarch 2014), with nine cases resulting in one
death. This lengthy outbreak was punctuated by some unusually
long gaps between cases; the reason for this remains unclear.
Several cases related to this outbreak also occurred off of the
Princeton campus, including a student at a nearby college [46].
The outbreak at the University of California, Santa Barbara
included four cases that occurred within a few weeks in
November 2013. This was a more typical outbreak, with short
intervals between cases. Further examination of cases led to the
discovery of a related case that occurred on the campus seven
months earlier. The four students survived, but one student
suffered bilateral foot amputations [47].
Since no FDA-licensed serogroup B vaccine was available at
the time of these outbreaks, 4CMenB, on an investigational new
drug protocol in collaboration with the Centers for Disease
Control and Prevention, was used to control these two outbreaks
[47]. A two-dose immunization series with 4CMenB was rec-
ommended for approximately 7,500 undergraduates, faculty, and
staff at Princeton and for 20,000 individuals at the University of
California, Santa Barbara [52]. Approximately, 90% of the target
population at Princeton University received both doses of
4CMenB; two-dose uptake was 37% at the University of Califor-
nia, Santa Barbara [47,53]. Differences in uptake at these two
college campuses is likely multifactorial, including differences in
campus structure, timing of immunization relative to serogroup
B cases, and perceived risk among students and parents. It should
be noted that these universities did a remarkable job managing
this outbreak, considering the detailed logistical planning that
was required for the 4CMenB immunization campaign.
A third, unrelated outbreak occurred at Providence College in
Rhode Island in early 2015, with two students hospitalized.
Because bivalent rLP2086 was FDA-licensed and available before
the start of this outbreak, the university moved quickly to
implement a mandatory campus-based mass immunizationcampaign for their undergraduate students. Over two days in
early February, 3,525 (94%) of the 3,745 vaccine-eligible student
population received bivalent rLP2086 [54]. Doses 2 and 3 of
bivalent rLP2096 were scheduled for April and September [45].
Data regarding exact coverage of Doses 2 and 3 have not yet
been released; however, uptake was likely high because stu-
dents had to actively opt out of receiving vaccination. No other
cases were identiﬁed as of early June 2015. It should be noted,
however, that it is difﬁcult to determine what effect the single
dose of bivalent rLP2086 had in this circumstance because the
correlate of efﬁcacy in clinical studies is measured after two or
three doses.
Finally, a fourth serogroup B outbreak at the University of
Oregon has been actively managed since the beginning of 2015,
with seven cases reported as of May 2015; one student died
[48,55]. A four-day campus-based mass immunization clinic to
administer bivalent rLP2086 was held in early March 2015 for
22,000 students, faculty, and staff. Almost 10,000 students
received their ﬁrst of three doses of bivalent rLP2086 during the
March clinic, but the second immunization clinic, which was
held in May, was attended by only 2,700 individuals; a third
clinic was held in October 2015 [49,50,56]. The total number of
students vaccinated is unknown, but it is estimated that>15,000
doses of vaccine have been administered to students through a
combination of university-sponsored clinics and vaccination at
local pharmacies [56].
Through experiences with outbreaks on U.S. college cam-
puses, it has been demonstrated that great effort can assure good
uptake, at least for the initial vaccine dose; however, current
MnB vaccine formulations require two or three doses, months
apart, to provide protection, a fact that obviously is not ideal in an
outbreak situation. In the future, it would be best to have pro-
tection before college entrance. Even if an MnB vaccine series
was completed before entering college, it is unknown whether
the protectionwould last through graduation. Further studies are
needed to determine the ideal path forward to provide protec-
tion against serogroup B IMD in college students.
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Implications of a category B Advisory Committee on
Immunization Practices recommendation
These recent outbreaks of serogroup B IMD on college cam-
puses illustratewhy the ACIP recommends routine use of anMnB
vaccine as a controlmeasure. However, the burden of serogroup B
IMD in older adolescents and young adults 18e23 years of age in
the United States is low (i.e., an estimated 15e30 cases annually
[57]). Among this age group, the incidence of MnB is estimated at
.14 per 100,000 [27]. Taken together with the considerable cost of
a routine immunization program targeting all individuals of this
age group (i.e., college students [one third of serogroup B IMD
cases in this age group [57]] and individuals not attending col-
lege) and the paucity of safety data the ACIP does not currently
routinely recommend MnB vaccines in young adults [27]. Rather,
the recent recommendation that the MnB vaccine may be
administered to adolescents and adults aged 16 through 23 years
for short-term protection is a “Category B” recommendation,
which leaves the decision to immunize an individual in this age
group up to physicians and parents/patients [27].
The permissive nature of Category B recommendations may
potentially result in lower vaccine uptake compared with a
“routine” or “Category A” recommendation. Category B recom-
mendations rely on both the physician advising parents/patients
that the MnB vaccine could be given and the availability of the
vaccine in the doctor’s ofﬁce if the decision to vaccinate is made;
thus, only time will allow us to determine vaccine uptake.
Meanwhile, it is important to determine the potential effect of
these MnB vaccines on meningococcal carriage, and duration of
protection, as well as the effectiveness of different vaccination
strategies and their costs.
Recent projections indicate that 29 cases and ﬁve deaths are
potentially preventable with an MnB vaccination series admin-
istered at age 11, 16, and 18 years [27]; these numbers decrease to
nine and one, respectively, if only college students are vaccinated.
Estimates for the number needed to vaccinate to prevent one case
andonedeath suggest fewer patientswouldneed tobe vaccinated
to achieve positive outcomes by implementing an MnB vaccina-
tion series at earlier ages (i.e., number needed to vaccinate to
prevent one case and one death: 102,000 and 638,000, respec-
tively, for a vaccine series at age 11, 16, and 18 years; 368,000 and
2,297,000, respectively, for college student vaccination). Pro-
jections also indicate that the cost per quality-adjusted life years is
lower ($3.7 vs. 9.4million, respectively)when anMnBvaccination
series is implemented at a younger age [27].
Continued monitoring of the incidence of endemic serogroup
B disease is essential; IMD is currently at a historic low in the
United States [2] although this could change with introduction of
new clones. All these data, albeit challenging to collect given the
low burden of disease, will be needed if the ACIP is to revisit the
Category B recommendation in the future. Meanwhile, it will be a
necessary but enormous task to effectively educate the public
and providers about these new vaccines and how best to
implement the associated recommendations.
A vaccine that protects against major meningococcal
diseaseecausing serotypes
Currently, one meningococcal vaccine targets serogroups A, C,
W, and Yand another targets only serogroup B. The availability ofa single vaccine that could protect against all ﬁve serogroups
would simplify the meningococcal immunization schedule and
potentially increase meningococcal vaccine uptake. A pentava-
lent meningococcal A, B, C, W, and Y vaccine formulation is not
yet available but has been developed and was recently examined
in a small study in adolescents [58e60]; larger safety and
immunogenicity studies are in progress [61]. Preliminary results,
identifying the most optimal formulation for future studies,
suggest all formulations tested have robust responses against all
ﬁve meningococcal serogroups, albeit responses were somewhat
higher for vaccine formulations containing outer membrane
vesicles (OMVs). No safety concerns have been identiﬁed thus far.
Because recommendations currently list serogroup A, C, W, Y
vaccines as Category A versus the Category B recommendation
for serogroup B vaccines in persons 16 through 23 years without
increased risk conditions, whether the availability of a pentava-
lent vaccine would qualify it for a Category A recommendation
remains to be determined. Moreover, it should be noted that
although development of such a vaccine is underway, the actual
availability of a pentavalent vaccine for inclusion into the
immunization schedule is years away. The dynamic nature of
IMD limits predictions of how this type of vaccine could actually
change the immunization landscape when it is FDA-licensed and
available for use.
Education
Continued educational programs will be needed to inform
physicians and the general public about the risks of IMD, avail-
able vaccines, strategies for prevention, and approaches to
improve vaccine uptake. Effective interventions include setting
up systems in health care clinics to facilitate parental and pro-
vider reminders of upcoming and overdue immunizations,
development of state laws for primary/secondary school and
college entry, educating providers on how to talk to parents, and
elucidating the best practices for implementation of old and new
vaccine recommendations, including the need for a booster dose
of the ACWY conjugate vaccine and immunization with the new
MnB vaccine.
Protecting infants
Infants represent an age group with some of the highest
incidence rates of IMD in the United States across disease-
causing serogroups although the majority (60%) of disease in
this age group is caused by serogroup B [2,62]. Routine vacci-
nation of infants for meningitis is not a standard practice in the
United States; however, MenACWY-D, MenACWY-CRM, and Hib-
MenCY-TT are recommended for use in high-risk infants
(Table 1). At present, neither of the MnB vaccines is currently
FDA-licensed or ACIP-recommended for use in infants. In studies
evaluating both currently available MnB vaccines in infants,
reactogenicity, in particular high fever, was common [63e65]
although most cases were mild to moderate in intensity and
short-lived. If immunization in infants is not possible owing to
considerable reactogenicity [63e65], infants must rely on either
maternally transmitted protective antibodies from their immu-
nized mother or on indirect protection (or herd immunity) from
their immunized contacts. However, at present, there are no data
available to suggest these are viable options.
Although beyond the scope of this review, it is important to
acknowledge that other countries besides the United States
C.J. Baker / Journal of Adolescent Health 59 (2016) S29eS37S36recommend routine meningococcal vaccination for infants as
part of their national immunization programs [29]. Opportunity
may exist to learn from the experiences of these countries with
regards to infant vaccination.
IMD is a rapid and unpredictable illness, leaving substantial
morbidity and mortality among those who are afﬂicted.
Although implementation of MenACWY immunization recom-
mendations was accompanied by a substantial decrease in the
incidence of N meningitidis infection in adolescents age
11e18 years, protection was short lived, requiring a booster dose
to protect through late adolescence [2,43]. Furthermore, a critical
gap in the prevention of MnB disease remained, especially
among infants. Whether the recent approval of two serogroup B
vaccines effectively ﬁlls this gap in coverage remains to be
determined. In the interim, some optimism is needed for their
potential effectiveness. Further complicating their potential
effectiveness, the recent Category B recommendation for the use
of MnB vaccines may prove difﬁcult to implement. Whether
these recommendations are enough to promote uptake
adequately to prevent outbreaks or to provide herd protection to
unvaccinated individuals needs to be determined.
The recent outbreaks of MnB disease on college campuses in
the United States serve as cruel reminders of the devastating
effects that outbreaks have in a community. Going forward, we
must heed the lessons learned from these experiences should
future outbreaks occur. Prevention of serogroup B disease in in-
fants remains an ongoing priority, but doing so will be chal-
lenging. Increasing awareness among clinicians and the public
regarding meningococcal immunization in high-risk individuals
in all age groups and those age groups with the highest disease
burden remains essential for success.
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